Wealthfront Advisers LLC Makes New Investment in Solventum Corporation $SOLV

Wealthfront Advisers LLC bought a new position in shares of Solventum Corporation (NYSE:SOLV) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 3,474 shares of the company’s stock, valued at approximately $263,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. State of New Jersey Common Pension Fund D raised its position in shares of Solventum by 4.3% in the second quarter. State of New Jersey Common Pension Fund D now owns 48,499 shares of the company’s stock worth $3,678,000 after buying an additional 2,018 shares in the last quarter. Sector Gamma AS raised its position in shares of Solventum by 26.7% in the second quarter. Sector Gamma AS now owns 38,000 shares of the company’s stock worth $2,882,000 after buying an additional 8,000 shares in the last quarter. IMG Wealth Management Inc. purchased a new stake in shares of Solventum in the second quarter worth $31,000. DekaBank Deutsche Girozentrale purchased a new stake in shares of Solventum in the second quarter worth $3,385,000. Finally, Chevy Chase Trust Holdings LLC raised its position in shares of Solventum by 1.0% in the second quarter. Chevy Chase Trust Holdings LLC now owns 73,612 shares of the company’s stock worth $5,583,000 after buying an additional 749 shares in the last quarter.

Solventum Stock Down 0.3%

Shares of NYSE:SOLV opened at $69.04 on Friday. The company has a current ratio of 1.22, a quick ratio of 0.86 and a debt-to-equity ratio of 2.14. The stock has a market capitalization of $11.97 billion, a P/E ratio of 31.96, a price-to-earnings-growth ratio of 2.80 and a beta of 0.50. Solventum Corporation has a 12-month low of $60.70 and a 12-month high of $85.92. The stock’s 50-day moving average price is $72.41 and its 200-day moving average price is $72.33.

Solventum (NYSE:SOLV) last posted its earnings results on Thursday, August 7th. The company reported $1.69 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.45 by $0.24. The company had revenue of $2.16 billion for the quarter, compared to analysts’ expectations of $2.12 billion. Solventum had a return on equity of 29.93% and a net margin of 4.52%.Solventum’s quarterly revenue was up 3.8% on a year-over-year basis. During the same period last year, the firm earned $1.56 earnings per share. Solventum has set its FY 2025 guidance at 5.800-5.950 EPS. On average, equities analysts anticipate that Solventum Corporation will post 6.58 earnings per share for the current year.

Analyst Ratings Changes

SOLV has been the topic of a number of recent analyst reports. Weiss Ratings reiterated a “hold (c)” rating on shares of Solventum in a research report on Thursday. Jefferies Financial Group assumed coverage on Solventum in a research report on Thursday, September 11th. They issued a “hold” rating and a $80.00 price objective on the stock. Wall Street Zen downgraded Solventum from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, September 9th. Morgan Stanley upgraded Solventum from an “equal weight” rating to an “overweight” rating and raised their price target for the company from $80.00 to $103.00 in a research report on Tuesday, July 15th. Finally, Wells Fargo & Company raised their price target on Solventum from $79.00 to $82.00 and gave the company an “equal weight” rating in a research report on Monday, September 15th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $84.89.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.